Glenmark arm enters into pact with Hengrui Pharma for trastuzumab rezetecan
This story was originally published at 16:28 IST on 24 September 2025
Register to read our real-time news.Informist, Wednesday, Sept. 24, 2025
--Glenmark subsidiary inks pact with Hengrui Pharma for trastuzumab rezetecan
--Glenmark arm gets exclusive rights to develop, sell trastuzumab rezetecan
--Glenmark to pay $18-mln upfront, up to $1.09 bln on milestones to Hengrui
MUMBAI – Glenmark Pharmaceuticals Ltd. Wednesday said its wholly-owned subsidiary Glenmark Specialty S.A. has entered into a licensing agreement with Hengrui Pharma for trastuzumab rezetecan, also known as SHR-A1811, a next-generation antibody-drug conjugate directed at the human epidermal growth factor receptor-2, or HER2. Glenmark Pharma will make an upfront payment of $18 million for the exclusive right to develop and commercialise trastuzumab rezetecan around the world, excluding China, Hong Kong, Taiwan, the US, Canada, Europe, Japan, Russia, Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Moldova, Tajikistan, Turkmenistan, and Uzbekistan, the company said in an exchange filing.
Hengrui Pharma will be eligible to receive regulatory and commercial milestone payments of up to $1.093 billion. Based on the net sales of trastuzumab rezetecan within the licensed territory, Glenmark Pharma will pay corresponding royalties to Hengrui Pharma, the company said in its filing.
Trastuzumab rezetecan was developed by Hengrui Pharma. In May, it was approved in China for the treatment of adult patients with unresectable locally advanced or metastatic non-small-cell lung cancer with an activating human epidermal growth factor receptor-2 mutation who have received at least one prior systemic therapy, as per the filing.
Glenmark Pharma had reported a consolidated net profit of INR 468.71 million for the June quarter on a revenue of INR 32.64 billion. Wednesday, shares of the company closed almost flat at INR 2,018.60 on the National Stock Exchange. End
US$1 = INR 88.69
Reported by Pooja Sawant
Edited by Rajeev Pai
For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.
Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.
Informist Media Tel +91 (22) 6985-4000
Send comments to feedback@informistmedia.com
© Informist Media Pvt. Ltd. 2025. All rights reserved.
To read more please subscribe
Share this Story:
